Does intravenous methocarbamol (Robaxin) cause decreased gastrointestinal motility?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 3, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Does IV Robaxin Cause Decreased GI Motility?

No, IV methocarbamol (Robaxin) does not cause decreased gastrointestinal motility based on available evidence. The FDA-approved prescribing information for IV Robaxin does not list decreased GI motility, constipation, or any motility-related effects among its adverse reactions 1.

Evidence from FDA Drug Label

The official FDA label for IV Robaxin lists the following gastrointestinal adverse reactions: dyspepsia, jaundice (including cholestatic jaundice), nausea, and vomiting 1. Notably absent from this list are any effects on GI motility, constipation, or intestinal transit time.

Mechanism of Action

Methocarbamol is described as a central nervous system (CNS) depressant with sedative and musculoskeletal relaxant properties 1. Its mechanism involves:

  • Blocking muscular Nav 1.4 sodium channels in skeletal muscle 2
  • CNS depression without direct effects on smooth muscle of the GI tract
  • No anticholinergic properties that would typically slow GI motility

Comparison to Drugs That DO Affect GI Motility

The evidence clearly identifies drugs that genuinely decrease GI motility, and methocarbamol is not among them:

Drugs that inhibit intestinal motility include:

  • Opioids (loperamide, codeine, diphenoxylate) 3
  • Anticholinergics (dicycloverine, propantheline, hyoscine butylbromide) 4
  • Tricyclic antidepressants 5
  • Calcium channel blockers 4
  • Clonidine 4

These agents work through specific mechanisms (opioid receptors, muscarinic receptors, calcium channels) that directly affect intestinal smooth muscle or the enteric nervous system 4.

Clinical Context

When guidelines discuss drugs affecting GI motility in various conditions (gastroparesis, short bowel syndrome, intestinal dysmotility), methocarbamol is never mentioned 3, 4, 3, 5, 6. This absence is significant given the comprehensive nature of these reviews.

Important Caveat

While methocarbamol itself does not decrease GI motility, it is often prescribed alongside opioid analgesics for musculoskeletal pain. If a patient on IV Robaxin develops constipation or decreased GI motility, the culprit is almost certainly the concurrent opioid medication, not the methocarbamol 4, 3.

The research confirms that opioids profoundly inhibit intestinal motility and delay gastric emptying 7, 8, which has significant clinical and therapeutic implications. This effect is well-documented and consistent across the literature.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.